GURU.Markets stock price, segment price, and overall market index valuation
The company's share price NeoGenomics Inc.
NeoGenomics is a major oncology laboratory providing genetic testing services. Its stock price reflects the growth of personalized medicine, but also intense competition and challenges with profitability in a complex healthcare pricing system.
Share prices of companies in the market segment - Chemistry
NeoGenomics is a leading oncology laboratory with two segments: clinical services (diagnostic tests) and pharmaceutical services (drug development assistance). We classify it as part of the Chemistry sector, and the chart below reflects the dynamics of the entire life sciences industry, which is dependent on R&D spending.
Broad Market Index - GURU.Markets
NeoGenomics is a leading oncology laboratory, offering a wide range of genetic and molecular tests for cancer diagnostics. As a component of the GURU.Markets index, it is at the forefront of personalized medicine. The chart below represents the entire market. See how NeoGenomics shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
NEO - Daily change in the company's share price NeoGenomics Inc.
Change_co for NeoGenomics, a cancer diagnostics lab, reflects volatility in the healthcare sector. Daily fluctuations demonstrate sensitivity to testing volumes and pricing changes. On System.GURU.Markets, this metric is important for analyzing companies in the medical diagnostics sector.
Daily change in the price of a set of shares in a market segment - Chemistry
NeoGenomics, Inc. is a laboratory specializing in cancer diagnostics. This chart highlights the highly volatile healthcare sector. Comparing it to NEO, whose business relies on the number of cancer tests, helps us understand it as a barometer of the industry.
Daily change in the price of a broad market stock, index - GURU.Markets
NeoGenomics is a leading oncology laboratory providing genetic testing for cancer diagnosis and personalized treatment. The oncology diagnostics sector is extremely sensitive to clinical data. The chart below illustrates the volatility in this niche, reflecting both high expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization NeoGenomics Inc.
NeoGenomics is a leader in cancer diagnostics. Its year-over-year performance reflects rapid growth in testing volumes and investor confidence in the potential of its technologies for early disease detection. The chart below shows the history of this science-intensive business.
Annual dynamics of market capitalization of the market segment - Chemistry
NeoGenomics, Inc. is a leading oncology laboratory offering a wide range of diagnostic tests. This chart shows how its leadership in this field, acquisition strategy, and competition in the rapidly expanding genetic testing sector are impacting its performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
NeoGenomics, a cancer diagnostics company, operates in the defensive healthcare sector. Demand for cancer tests is unaffected by economic cycles. The company's stock price reflects the long-term trend toward personalized medicine, providing it with sustainable growth potential.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization NeoGenomics Inc.
NeoGenomics, a leading oncology laboratory providing diagnostic testing services. The monthly fluctuations on the chart reflect the volume of tests performed, which depends on the number of cancer diagnoses, and the introduction of new, more sophisticated genetic tests.
Monthly dynamics of market capitalization of the market segment - Chemistry
NeoGenomics is a leading oncology laboratory offering a wide range of genetic and molecular tests for cancer diagnosis and treatment selection. Demand for its services is growing alongside the advancement of personalized medicine. The dynamics of the medical testing and diagnostics sector reflects overall trends and investments in this cutting-edge area of healthcare.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Oncology diagnostics stocks are a growth story in the defensive healthcare sector. The chart below shows the overall market sentiment. Is NeoGenomics moving in sync with the growth market, or does its medical focus provide stability?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization NeoGenomics Inc.
Shares of NeoGenomics, a cancer diagnostics company, fluctuate weekly based on biotech news. Announcements of new tests, changes in insurance coverage for diagnostics, and research results confirming the accuracy of their tests prompt rapid market reactions.
Weekly dynamics of market capitalization of the market segment - Chemistry
NeoGenomics shares, like those of the entire oncology diagnostics sector, are moving against the backdrop of scientific breakthroughs and changes in the healthcare system. Insurance company reimbursement policies for testing are a common driver for all. The chart will show how the company stacks up in this competitive environment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
NeoGenomics, as a healthcare company, may exhibit defensive properties. Demand for oncology diagnostics is independent of economic conditions. The chart allows us to compare its performance with the S&P 500 and determine whether it represents a safe haven during market downturns.
Market capitalization of the company, segment and market as a whole
NEO - Market capitalization of the company NeoGenomics Inc.
The NeoGenomics market capitalization chart is the financial valuation of a leading laboratory specializing in oncology testing. It reflects the demand for sophisticated cancer diagnostics from physicians and pharmaceutical companies. Its dynamics tell the story of how personalized medicine and drug development are driving the need for accurate genetic diagnostics.
NEO - Share of the company's market capitalization NeoGenomics Inc. within the market segment - Chemistry
NeoGenomics provides oncology diagnostic tests and laboratory services. Its market share reflects its key role in personalized medicine. The chart shows the company's importance as a key partner for oncologists and pharmaceutical companies, helping to select the most effective cancer treatments.
Market capitalization of the market segment - Chemistry
NeoGenomics is a laboratory specializing in oncology diagnostics. The chart below, showing the overall value of the chemical industry, provides only a general overview. NeoGenomics operates at the intersection of medicine and chemistry, and the dynamics of healthcare investments provide the true context for its business valuation.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cancer diagnostics is a cutting-edge field of medicine, generating enormous value. NeoGenomics provides laboratory services to oncologists, helping them choose personalized treatment. Its market capitalization reflects its role in modern oncology and the development of targeted therapy.
Book value capitalization of the company, segment and market as a whole
NEO - Book value capitalization of the company NeoGenomics Inc.
For NeoGenomics, a leader in oncology diagnostics, this chart represents the material foundation for the fight against cancer. The growth in book value reflects the expansion of its network of advanced laboratories equipped with sophisticated genetic testing equipment. These are physical assets that help doctors make accurate diagnoses.
NEO - Share of the company's book capitalization NeoGenomics Inc. within the market segment - Chemistry
NeoGenomics, which specializes in oncology diagnostics, has a network of high-tech laboratories. Its share of the sector's assets includes buildings and advanced genetic testing equipment. This physical infrastructure underpins its ability to process complex tests for physicians across the country.
Market segment balance sheet capitalization - Chemistry
In the capital-intensive healthcare sector, NeoGenomics occupies a knowledge-intensive niche. The industry's asset chart reflects the value of hospitals. NeoGenomics, on the other hand, invests in cutting-edge laboratories, which are its primary asset for conducting oncology tests.
Book value of all companies included in the broad market index - GURU.Markets
NeoGenomics is a laboratory helping fight cancer. Its assets are state-of-the-art diagnostic equipment, automated laboratories in the US and Europe, and vast databases of genetic information. This is the physical and informational foundation for precision oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - NeoGenomics Inc.
NeoGenomics is a high-tech laboratory. Its assets include expensive equipment. But the market pays a premium for its leadership in oncology diagnostics, its vast databases, and its indispensable role in personalized medicine, which constitutes its main intangible assets.
Market to book capitalization ratio in a market segment - Chemistry
NeoGenomics provides oncology tests, aiding in the diagnosis and treatment of cancer. The company's value lies in its technologies and patents, not its physical laboratories. This chart reflects how highly the market values its scientific developments and market share compared to its tangible assets, which is typical for the biotech sector.
Market to book capitalization ratio for the market as a whole
NeoGenomics is a laboratory specializing in genetic testing for cancer diagnosis and treatment. Compared to average market valuations shown in this chart, its premium reflects its leadership in cancer diagnostics and the growing demand for personalized medicine, which investors value above tangible assets.
Debts of the company, segment and market as a whole
NEO - Company debts NeoGenomics Inc.
NeoGenomics provides oncology testing and diagnostic services, helping doctors choose treatments. It's a knowledge-intensive business, requiring ongoing investment in laboratory equipment and research. Debt capital can serve as a source of funding for acquiring new technologies and expanding the range of tests offered, as reflected in the dynamics in this chart.
Market segment debts - Chemistry
NeoGenomics provides oncology testing and laboratory services. This is a knowledge-intensive industry that requires constant investment in new equipment and research. Companies in this sector can use debt to finance acquisitions or expand laboratory capacity. This chart shows how NeoGenomics manages its finances to maintain its technological leadership.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio NeoGenomics Inc.
NeoGenomics provides oncology diagnostic services that require ongoing investment in equipment and research. This chart shows the extent to which the company finances its operations with debt. This provides investors with an understanding of its financial risks: whether the company will be able to service its debt if it faces increased competition or delays in developing new tests.
Market segment debt to market segment book capitalization - Chemistry
NeoGenomics provides complex oncology tests that require advanced equipment and ongoing research. This chart shows the collective debt burden in the biotech and diagnostics sector. It helps us understand how NeoGenomics' debt strategy for funding innovation and growth aligns with overall trends in this capital-intensive scientific industry.
Debt to book value of all companies in the market
NeoGenomics specializes in genetic testing for cancer diagnostics. This is a knowledge-intensive industry that requires constant investment in research and new equipment. This chart shows the overall sentiment in the credit markets, which helps us understand whether NeoGenomics is pursuing debt financing to accelerate development or relying on equity.
P/E of the company, segment and market as a whole
P/E - NeoGenomics Inc.
This chart for NeoGenomics, a laboratory specializing in cancer diagnostics, shows a high valuation typical of the biotech sector. The P/E reflects not only current revenue from genetic testing but also the enormous growth potential in the field of personalized medicine, where accurate diagnostics are key to cancer treatment.
P/E of the market segment - Chemistry
NeoGenomics specializes in genetic and molecular testing for cancer diagnosis and treatment, serving oncologists and pharmaceutical companies. This chart shows the average rating for the biotech and diagnostics sector, helping to understand the market's perception of NeoGenomics' role in the future of personalized medicine.
P/E of the market as a whole
NeoGenomics is a laboratory specializing in oncology testing and research. Demand for its services is driven by the number of cancer diagnoses and the volume of pharmaceutical R&D, not economic cycles. This general sentiment trend has little impact on its business. For NeoGenomics, demographic trends and innovations in cancer treatments, which drive long-term demand, are far more important.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company NeoGenomics Inc.
NeoGenomics provides oncology tests and diagnostic services, helping doctors fight cancer. Demand for their services is growing alongside the advancement of personalized medicine. This chart shows analysts' estimates of the company's future revenue stream from new tests and partnerships, reflecting profitability expectations in light of innovations in cancer diagnostics.
%20P%2FE%20NeoGenomics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-NeoGenomics-Inc.&v=1772513537618 "Chart of the company's future (projected) P/E NeoGenomics Inc.")
Future (projected) P/E of the market segment - Chemistry
NeoGenomics specializes in genetic cancer testing, helping doctors choose the right treatment. This chart illustrates the average profitability forecast for diagnostic and research companies. NEO's position relative to this metric reflects investors' confidence in its technology platform and the company's ability to commercialize new tests faster than competitors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Chemistry&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Chemistry&v=1772513537642 "Future (projected) P/E graph of the market segment - Chemistry")
Future (projected) P/E of the market as a whole
NeoGenomics provides oncology tests, being at the forefront of the fight against cancer. The valuation of such science-intensive companies depends on investors' appetite for risk and long-term ideas. This chart shows the overall market sentiment. During periods of optimism, capital is more willing to invest in innovative medicine, supporting companies like NeoGenomics.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513537648 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit NeoGenomics Inc.
NeoGenomics is a high-tech laboratory specializing in genetic testing for cancer diagnosis and treatment. The chart illustrates the financial results of their scientific and commercial activities. Increasing the number of tests and developing new diagnostic panels are key drivers of the company's growth and profitability.
Profit of companies in the market segment - Chemistry
NeoGenomics provides oncology testing and diagnostic services, playing a vital role in cancer treatment. The company's business is sensitive to healthcare spending and scientific breakthroughs. This chart shows the overall profitability of its sector. It helps understand global trends in oncology funding and the adoption of new diagnostic technologies that shape the market environment for NeoGenomics.
Overall market profit
NeoGenomics, which specializes in cancer genetic testing, is a vital player in healthcare. During periods of rising overall corporate profits, as reflected in the graph, clinics and patients have more resources to invest in advanced diagnostics. This directly impacts NeoGenomics' demand and revenue, making its success an indicator of not only patient health but also the health of the economy.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company NeoGenomics Inc.
NeoGenomics is a laboratory specializing in genetic testing for cancer diagnosis and treatment. The company's future profits are directly tied to the development of new tests and their implementation in clinical practice. This chart demonstrates analysts' expectations for the commercial success of its oncology testing portfolio and the growing demand for personalized medicine.
%20profit%20of%20the%20company%20NeoGenomics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-NeoGenomics-Inc.&v=1772513537684 "Graph of future (projected) profit of the company NeoGenomics Inc.")
Future (predicted) profit of companies in the market segment - Chemistry
NeoGenomics provides cutting-edge diagnostic tests for oncology, helping doctors choose treatments. The company's success depends on innovations in cancer genetics and partnerships with pharmaceutical giants. This chart reflects analyst profitability forecasts for the entire biotech sector, allowing one to assess NeoGenomics' potential in the context of overall industry trends.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Chemistry&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Chemistry&v=1772513537759 "Graph of future (predicted) profits of companies in a market segment - Chemistry")
Future (predicted) profit of the market as a whole
NeoGenomics provides cancer tests, the demand for which is less elastic with respect to economic cycles. People are not delaying cancer screenings. However, the overall economic situation, reflected in the graph, affects the solvency of patients and insurance companies, as well as the funding of new research in the industry.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513537768 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - NeoGenomics Inc.
NeoGenomics provides sophisticated oncology tests, aiding in the diagnosis and treatment of cancer. This chart shows the market's high valuation of its revenue, anticipating breakthroughs in personalized medicine. This metric's dynamics reflect investors' faith in the company's scientific potential and future demand for its innovative diagnostic services.
P/S market segment - Chemistry
NeoGenomics specializes in genetic tests for cancer diagnostics, where revenue comes from fees for complex laboratory testing. This metric illustrates the average revenue estimate in the biotech sector. Comparisons with this metric help understand the market's perceived value for the scientific expertise and commercial potential of NeoGenomics' diagnostic platforms.
P/S of the market as a whole
NeoGenomics specializes in genetic testing for cancer diagnosis and treatment. The company's revenue depends on the number of tests performed and the implementation of new oncology technologies. This chart shows the average market revenue estimate, which helps understand how highly investors value NeoGenomics' research-intensive and fast-growing business compared to other industries.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company NeoGenomics Inc.
NeoGenomics specializes in genetic testing for cancer diagnosis and treatment, providing critical information to oncologists. This chart shows how investors view the company's future revenue. The trend reflects expectations for the introduction of new tests, an expanding client base among clinics and pharmaceutical companies, and confidence in its scientific potential.
%20P%2FS%20NeoGenomics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-NeoGenomics-Inc.&v=1772513537805 "The graph of the company's future (projected) P/S NeoGenomics Inc.")
Future (projected) P/S of the market segment - Chemistry
NeoGenomics specializes in cancer genetic testing, providing oncologists and pharmaceutical companies with critical information for diagnosis and treatment. This chart shows how the market values the company's future revenue. A high valuation indicates confidence in the growth of personalized medicine, while a lower valuation reflects intense competition in the oncology diagnostics field.
%20P%2FS%20market%20segment%20graph%20-%20Chemistry&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Chemistry&v=1772513537824 "Future (projected) P/S market segment graph - Chemistry")
Future (projected) P/S of the market as a whole
NeoGenomics provides oncology tests, assisting in the diagnosis and treatment of cancer. Demand for its services is driven by medical needs, not economic cycles. In the overall revenue growth picture illustrated by the chart, NeoGenomics represents the innovative healthcare sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513537846 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales NeoGenomics Inc.
NeoGenomics is a laboratory specializing in oncology testing. Its revenue, reflected in this chart, comes from providing a wide range of genetic and molecular tests to pharmaceutical companies for clinical trials and to oncologists for cancer diagnosis and treatment. Demand for personalized medicine is a key growth driver.
Sales of companies in the market segment - Chemistry
NeoGenomics (NEO) specializes in genetic testing for oncology, helping doctors develop personalized cancer treatments. The company's laboratories analyze tumors at the molecular level. This chart reflects the overall revenue of the chemical-biological sector, in which NeoGenomics is a key player, advancing cutting-edge diagnostic and therapeutic methods.
Overall market sales
NeoGenomics provides sophisticated cancer testing, helping doctors choose treatments. While demand for its services is primarily driven by health, the broader economic picture reflected here is important. Economic growth ensures stable funding for healthcare systems and expanded insurance coverage, making advanced diagnostic tests more accessible to patients.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company NeoGenomics Inc.
NeoGenomics specializes in genetic testing for cancer diagnosis and treatment. The company's future revenue depends on demand for cancer tests from clinics and pharmaceutical companies. This chart shows analysts' revenue growth expectations, reflecting advances in personalized medicine and the introduction of new diagnostic platforms.
%20sales%20of%20the%20company%20NeoGenomics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-NeoGenomics-Inc.&v=1772513537972 "Schedule of future (projected) sales of the company NeoGenomics Inc.")
Future (projected) sales of companies in the market segment - Chemistry
NeoGenomics is a high-tech laboratory specializing in cancer diagnostics. This chart shows revenue forecasts for two main segments: clinical services (tests for hospitals) and pharmaceutical services (drug development support). This provides insight into which segment, according to analysts, will grow most rapidly.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Chemistry&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Chemistry&v=1772513537983 "Schedule of future (projected) sales of companies in the market segment - Chemistry")
Future (projected) sales of the market as a whole
NeoGenomics provides cancer testing and laboratory services to pharmaceutical companies and clinics. Demand for its services depends on the volume of cancer research and the number of patients diagnosed. This demand, reflecting the overall economic situation, impacts healthcare budgets and R&D funding, on which NeoGenomics' business depends.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513538014 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality NeoGenomics Inc.
NeoGenomics provides cancer testing and laboratory services, helping doctors choose treatment options. The company's profitability depends on testing volume, insurance reimbursement, and investments in new technologies. The chart demonstrates how the company translates its scientific developments and diagnostic services into financial returns for its shareholders.
Market segment marginality - Chemistry
NeoGenomics is a leading oncology diagnostic laboratory, providing a wide range of genetic tests to physicians and pharmaceutical companies. This chart shows the profitability of its laboratory business. Success depends on the volume of tests performed, the implementation of new technologies, and partnerships in clinical research.
Market marginality as a whole
NeoGenomics provides complex oncology diagnostic tests that require significant investment from healthcare systems and patients. This chart reflects the overall financial health of the corporate sector. Stable or growing economic profitability allows insurance companies and hospitals to allocate more funds to advanced medical technologies, supporting demand.
Employees in the company, segment and market as a whole
Number of employees in the company NeoGenomics Inc.
NeoGenomics is a high-tech laboratory specializing in oncology diagnostics. Its core assets are its scientists, pathologists, and laboratory technicians. The staff increase, reflected in the graph, is directly related to the growth of testing volumes, the launch of new diagnostic tests, and expanded partnerships with pharmaceutical companies.
Share of the company's employees NeoGenomics Inc. within the market segment - Chemistry
NeoGenomics is at the forefront of the fight against cancer, providing sophisticated genetic testing. In the field of laboratory diagnostics, its highly qualified scientists and technicians are a key asset. This chart reflects the scale of its research and diagnostic activities, demonstrating the human capital involved in analyzing complex biomaterials.
Number of employees in the market segment - Chemistry
NeoGenomics provides oncology testing and diagnostic services. The employment dynamics in the biotechnology and laboratory research sector, visible in this graph, demonstrate the industry's talent potential. For NeoGenomics, this means both access to highly qualified laboratory technicians and geneticists and increased competition for talent with competitors in the diagnostics industry.
Number of employees in the market as a whole
NeoGenomics is a clinical laboratory specializing in cancer diagnostics. Its growth is driven by advances in oncology and an aging population, making it resilient to short-term economic downturns. This graph shows the overall labor market, where the company is seeking highly specialized scientific and technical talent.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company NeoGenomics Inc. (NEO)
NeoGenomics is a leading oncology diagnostic laboratory. The company's business is based on cutting-edge scientific research and sophisticated laboratory equipment. This chart illustrates the enormous value the market places on the intellectual capital of its scientists and unique technologies, allowing each employee to generate a significant share of market capitalization.
%20of%20the%20company%20NeoGenomics%20Inc.%20(NEO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-NeoGenomics-Inc.-NEO&v=1772513538178 "Chart of market capitalization per employee (in thousands of dollars) of the company NeoGenomics Inc. (NEO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Chemistry
NeoGenomics specializes in genetic testing for cancer diagnostics. In this knowledge-intensive business, value is created not by production lines, but by experts and their developments. This metric reflects the premium the market is willing to pay for a company's intellectual capital and patents per highly qualified specialist.
%20by%20market%20segment%20-%20Chemistry&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Chemistry&v=1772513538201 "Market capitalization per employee (in thousands of dollars) by market segment - Chemistry")
Market capitalization per employee (in thousands of dollars) for the overall market
NeoGenomics specializes in genetic testing for cancer diagnosis and treatment. The chart shows the high value the market places on each employee of this research-intensive laboratory. This reflects the company's key asset: the expertise and qualifications of its scientists and technicians working with cutting-edge biotechnologies.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513538224 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company NeoGenomics Inc. (NEO)
NeoGenomics specializes in complex oncology diagnostics. Their "factory" is a laboratory staffed by highly qualified specialists. This metric reflects how efficiently the company processes tests and manages research costs. Growth speaks to lab automation and the high profitability of their diagnostic services.
%20Chart%20NeoGenomics%20Inc.%20(NEO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-NeoGenomics-Inc.-NEO&v=1772513538247 "Company Profit Per Employee (in thousands of dollars) Chart NeoGenomics Inc. (NEO)")
Profit per employee (in thousands of dollars) in the market segment - Chemistry
NeoGenomics operates a network of oncology laboratories, offering complex genetic testing and diagnostic services. This business requires highly qualified specialists. This chart shows how effectively the company balances personnel costs (doctors, technicians) with the volume of tests performed, as well as the implementation of automation in the laboratories.
%20in%20the%20market%20segment%20-%20Chemistry&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Chemistry&v=1772513538268 "Chart of profit per employee (in thousands of dollars) in the market segment - Chemistry")
Profit per employee (in thousands of dollars) for the market as a whole
NeoGenomics provides oncology testing and diagnostic services. It's a high-tech medical business, requiring sophisticated laboratory equipment and, more importantly, a team of highly qualified pathologists and geneticists. This indicator demonstrates how the company's biotechnology expertise creates significant added value, which directly impacts profitability per specialist.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513538301 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee NeoGenomics Inc. (NEO)
NeoGenomics provides oncology testing and laboratory services, helping doctors diagnose and treat cancer. Revenue per employee in this sector reflects the throughput of its laboratories and the value of their analyses. The chart shows how the company is scaling its operations to process an increasing number of samples, playing a key role in oncology.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-NeoGenomics-Inc.-NEO&v=1772513538316 "Sales chart per company employee NeoGenomics Inc. (NEO)")
Sales per employee in the market segment - Chemistry
NeoGenomics (NEO) is a technology company that operates a network of laboratories specializing in oncology diagnostics and genetic testing. This chart shows the average revenue per employee in the biotech segment. It helps assess how effectively NEO utilizes its scientific and laboratory staff to generate revenue.
Sales per employee for the market as a whole
NeoGenomics (NEO) specializes in complex cancer diagnostics, providing oncologists with critical genetic tests. It's a knowledge-intensive business where value is created by highly skilled lab technicians and pathologists. This metric reflects the productivity of their laboratories. It shows the company's revenue per specialist, which depends on the level of automation in test processing, their cost, and insurance reimbursement.
Short shares by company, segment and market as a whole
Shares shorted by company NeoGenomics Inc. (NEO)
NeoGenomics (NEO) provides sophisticated cancer diagnostic tests, supporting oncology and research. It's a cutting-edge but highly competitive industry. This chart shows the volume of shares being shorted. A rise in this indicator may reflect market concerns about the timing of new tests being approved, pricing pressure from competitors, or high cash burn. (344)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-NeoGenomics-Inc.-NEO&v=1772513538358 "Short Shares Chart for the Company NeoGenomics Inc. (NEO)")
Shares shorted by market segment - Chemistry
NeoGenomics is a high-tech laboratory specializing in genetic testing for cancer, helping doctors choose treatments. This chart shows the overall sentiment in the sector. It reflects investor concerns about profitability in the diagnostics sector and cuts in biotech R&D budgets.
Shares shorted by the overall market
NeoGenomics provides sophisticated oncology tests and diagnostics for laboratories and pharmaceutical companies. It's in the healthcare sector, but with a twist. Its clients (biotech companies) depend on R&D budgets. When this fear indicator rises, investors (and biotech companies) freeze research spending, reducing demand for NeoGenomics' diagnostic services.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator NeoGenomics Inc. (NEO)
NeoGenomics (NEO) is a major oncology laboratory. They provide genetic testing and cancer diagnostics for pathologists, oncologists, and pharmaceutical companies. This chart measures momentum. It shows "overbought" (above 70) amid rising testing volumes or "oversold" (below 30) amid news of reimbursement rate cuts or management issues.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-NeoGenomics-Inc.-NEO&v=1772513538430 "RSI 14 indicator chart for the company's stock NeoGenomics Inc. (NEO)")
RSI 14 Market Segment - Chemistry
NeoGenomics (NEO) is a leading oncology laboratory. They provide sophisticated genetic tests that help doctors select targeted therapies for cancer patients. This chart measures the pulse of the Diagnostics/Chemicals sector. It helps distinguish demand for NEO tests from general "overheating" or "overselling" in the biotech diagnostics industry.
RSI 14 for the overall market
NeoGenomics (NEO), a cancer diagnostics lab. This chart shows that its business is "defensive." Demand for cancer tests isn't affected by euphoria or panic. However, part of its business is R&D contracts with biotech companies. In times of panic, biotech companies "freeze" R&D, which could impact this segment, while the clinical segment remains stable.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NEO (NeoGenomics Inc.)
NeoGenomics (NEO) is a leading oncology diagnostic laboratory. The company provides a wide range of genetic and molecular tests to hospitals and oncologists, helping them tailor cancer treatments. This chart shows the average Wall Street forecast, reflecting analyst expectations for increased testing volumes and the introduction of new diagnostic platforms.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NEO-NeoGenomics-Inc.&v=1772513538551 "A chart showing analyst consensus forecasts for the expected stock price. NEO (NeoGenomics Inc.)")
The difference between the consensus estimate and the actual stock price NEO (NeoGenomics Inc.)
NeoGenomics (NEO) is a key laboratory in oncology. The company provides sophisticated genetic cancer tests to hospitals (helping doctors) and to the pharmaceutical industry (aiding drug R&D). This chart shows the difference between the consensus forecast and the price, reflecting analysts' confidence in the business's recovery.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NEO-NeoGenomics-Inc.&v=1772513538590 "A chart showing the difference between the consensus forecast and the actual stock price. NEO (NeoGenomics Inc.)")
Analyst consensus forecast for stock prices by market segment - Chemistry
NeoGenomics is a leading oncology laboratory providing comprehensive genetic and molecular testing for oncologists and pharmaceutical companies. This chart shows general expectations for the chemical sector (specifically diagnostics). It reflects whether experts believe demand for accurate cancer diagnostics will grow.
Analysts' consensus forecast for the overall market share price
NeoGenomics (NEO) is a diagnostics company. They provide oncology tests (genetics, pathology) for hospitals and pharmaceutical companies. This chart of overall market sentiment is important. Optimism = pharmaceutical companies (biotech) are actively spending on R&D (clinical trials), which translates into revenue for NEO.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index NeoGenomics Inc.
NeoGenomics (NEO) is a leading oncology laboratory. They provide a full range of genetic and molecular tests to hospitals and pharmaceutical companies, assisting in cancer diagnosis and treatment selection. This chart is an indicator of the demand for personalized oncology. It reflects the volume of their tests and their role in the R&D of new cancer drugs.
AKIMA Market Segment Index - Chemistry
NeoGenomics (NEO) is a leader in oncology diagnostics, providing a full range of business-to-business (B2B) laboratory tests (from genetics to cytology) for oncologists and pharmaceutical companies (CROs). This aggregate metric evaluates companies. The graph shows the sector average. This benchmark: how does this niche (cancer-only) diagnostic model (NEO) differentiate itself from the average competitor?
The AKIM Index for the overall market
NeoGenomics is a network of oncology laboratories providing genetic testing for physicians and pharmaceutical companies. This chart, reflecting the market average, provides context. It helps assess how NEO, a critical partner in cancer treatment, compares to overall macroeconomic trends and testing volumes.
